Cited by 175Parkinson's Disease Mechanisms and TreatmentsNuclear Receptors and SignalingMitochondrial Function and Pathology

The DOI matches its Crossref record; 95 of the 95 references it cites were found in a registry or an index.

Mitochondrial dysfunction in Parkinson's disease

Schapira, A H V·2007·Cell Death & Differentiation

DOI 10.1038/sj.cdd.4402160

Open this paper in CoChat — free account

Integrity signals

Registry

Crossref · 10.1038/sj.cdd.4402160

Cites

95 of 95 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The protein kinase complement of the human genome
Manning, G., Whyte, D. B., Martinez, R., Hunter, T., & Sudarsanam, S. (2002) · Science · doi:10.1126/science.1075762 · Cited by 8,145
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., & Shimizu, N. (1998) · Nature · doi:10.1038/33416 · Cited by 5,227
Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis
Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983) · Science · doi:10.1126/science.6823561 · Cited by 4,914
Chronic systemic pesticide exposure reproduces features of Parkinson's disease
Betarbet, R. S., Sherer, T., MacKenzie, G. M., Garcia‐Osuna, M., Panov, A. V., & Greenamyre, J. T. (2000) · Nature Neuroscience · doi:10.1038/81834 · Cited by 3,770
Mitochondrial membrane permeabilization in cell death
Kroemer, G., Galluzzi, L., & Brenner, C. (2007) · Physiological Reviews · doi:10.1152/physrev.00013.2006 · Cited by 3,598
Hereditary Early-Onset Parkinson's Disease Caused by Mutations in PINK1
Valente, E. M., Abou-Sleiman, P. M., Caputo, V., Muqit, M. M. K., Harvey, K., Gispert, S., Ali, Z., Del Turco, D., Bentivoglio, A. R., Healy, D. G., et al. (2004) · Science · doi:10.1126/science.1096284 · Cited by 3,481
Mutations in the DJ-1 Gene Associated with Autosomal Recessive Early-Onset Parkinsonism
Bonifati, V., Rizzu, P., van Baren, M. J., Schaap, O., Breedveld, G. J., Krieger, E., Dekker, M. C. J., Squitieri, F., Ibáñez, P., Joosse, M., et al. (2003) · Science · doi:10.1126/science.1077209 · Cited by 2,854
Signaling—2000 and Beyond
Hunter, T. (2000) · Cell · doi:10.1016/s0092-8674(00)81688-8 · Cited by 2,586
Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin
Clark, I. E., Dodson, M. W., Jiang, C., Cao, J. H., Huh, J. R., Seol, J. H., Yoo, S. J., Hay, B. A., & Guo, M. (2006) · Nature · doi:10.1038/nature04779 · Cited by 1,788
MITOCHONDRIAL COMPLEX I DEFICIENCY IN PARKINSON'S DISEASE
Schapira, A. H. V., Cooper, J. A. D., Dexter, D. T., Jenner, P. G., Clark, J. B., & MARSDEN, C. D. (1989) · The Lancet · doi:10.1016/s0140-6736(89)92366-0 · Cited by 1,757
Self-citation

Show all 95 references

Research works printed but not linked: 1

Valente EM et al. Science 2004; 304: 1158–1160. · DOI · Paper page

Sorted by citations

Parkinson disease
Poewe, W., Seppi, K., Tanner, C. M., Halliday, G. M., Brundin, P., Volkmann, J., Schrag, A.-E., & Lang, A. E. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.13 · Cited by 5,415
Selective neuronal vulnerability in Parkinson disease
Surmeier, D. J., Obeso, J. A., & Halliday, G. M. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2016.178 · Cited by 1,116
The PINK1/Parkin pathway regulates mitochondrial morphology
Poole, A. C., Thomas, R. E., Andrews, L. A., McBride, H. M., Whitworth, A. J., & Pallanck, L. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709336105 · Cited by 885
Analysis of mitochondrial function in situ in permeabilized muscle fibers, tissues and cells
Kuznetsov, A. V., Veksler, V., Gellerich, F. N., Saks, V. A., Margreiter, R., & Kunz, W. S. (2008) · Nature Protocols · doi:10.1038/nprot.2008.61 · Cited by 839
Etiology and pathogenesis of Parkinson's disease
Schapira, A. H. V., & Jenner, P. G. (2011) · Movement Disorders · doi:10.1002/mds.23732 · Cited by 703
Self-citation
Mitochondrial dysfunction and oxidative stress in Parkinson's disease and monogenic parkinsonism
Hauser, D. N., & Hastings, T. G. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.10.011 · Cited by 487
Mitochondrial Dysfunction in Parkinson’s Disease
Moon, H. E., & Paek, S. H. (2015) · Experimental Neurobiology · doi:10.5607/en.2015.24.2.103 · Cited by 455
The Mitochondrial Fusion-Promoting Factor Mitofusin Is a Substrate of the PINK1/Parkin Pathway
Poole, A. C., Thomas, R. E., Yu, S., Vincow, E. S., & Pallanck, L. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010054 · Cited by 440
Mitochondrial respiratory complex I: Structure, function and implication in human diseases
Sharma, L., Lu, J., & Bai, Y. (2009) · Current Medicinal Chemistry · doi:10.2174/092986709787846578 · Cited by 438
Mitochondria and Quality Control Defects in a Mouse Model of Gaucher Disease—Links to Parkinson’s Disease
Osellame, L. D., Rahim, A. A., Hargreaves, I. P., Gegg, M. E., Richard-Loendt, A., Brandner, S., Waddington, S. N., Schapira, A. H. V., & Duchen, M. R. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.014 · Cited by 338
Self-citation
Mitochondrial Approaches for Neuroprotection
Chaturvedi, R. K., & Beal, M. F. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1427.027 · Cited by 294
Mitochondria: Sovereign of inflammation?
Tschopp, J. (2011) · European Journal of Immunology · doi:10.1002/eji.201141436 · Cited by 303
Exploring the Role of Neuroplasticity in Development, Aging, and Neurodegeneration
Marzola, P., Melzer, T., Pavesi, E., Gil-Mohapel, J., & Brocardo, P. S. (2023) · Brain Sciences · doi:10.3390/brainsci13121610 · Cited by 281
“PD is also associated with mitochondrial dysfunction, including impaired mitochondrial dynamics and oxidative stress [282], and oxidative stress has been linked to alpha-synuclein accumulation in dopaminergic neurons, a hallmark of the disease [283].”
Background
Role of Nitric Oxide Synthases in Parkinson’s Disease: A Review on the Antioxidant and Anti-inflammatory Activity of Polyphenols
Aquilano, K., Baldelli, S., Rotilio, G., & Ciriolo, M. R. (2008) · Neurochemical Research · doi:10.1007/s11064-008-9697-6 · Cited by 273
Inhibition of excessive mitochondrial fission reduced aberrant autophagy and neuronal damage caused by LRRK2 G2019S mutation
Su, Y.-C., & Qi, X. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt301 · Cited by 233
Copper and Copper Proteins in Parkinson’s Disease
Montes, S., Rivera-Mancia, S., Diaz-Ruiz, A., Tristan-Lopez, L., & Rios, C. (2014) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2014/147251 · Cited by 203
Roles of mitochondria in human disease
Duchen, M. R., & Szabadkai, G. (2010) · Essays in Biochemistry · doi:10.1042/bse0470115 · Cited by 171
Nature and cause of mitochondrial dysfunction in Huntington’s disease: focusing on huntingtin and the striatum
Oliveira, J. M. A. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06741.x · Cited by 163
“Just like mHtt is linked to HD, abnormal bamyloid (Ab) peptide processing is linked to AD, and mutations in a-synuclein, parkin, DJ-1, PINK1, and LRRK2 are linked to PD (Lin and Beal 2006; Schapira 2007; Gotz et al. 2009; Chan et al. 2009).”
Background
G2019S leucine-rich repeat kinase 2 causes uncoupling protein-mediated mitochondrial depolarization
Papkovskaia, T. D., Chau, K., Iñesta-Vaquera, F., Papkovsky, D. B., Healy, D. G., Nishio, K., Staddon, J. M., Duchen, M. R., Hardy, J., Schapira, A. H. V., et al. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds244 · Cited by 168
Self-citation
PPAR: a therapeutic target in Parkinson’s disease
Chaturvedi, R. K., & Beal, M. F. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05388.x · Cited by 151
“Decreased mitochondrial complex-I activity was observed in platelets, SN and skeletal muscle of PD patients (Bindoff et al. 1989; Schapira et al. 1990; Haas et al. 1995; Schapira 2007).”
3D Cultures of Parkinson's Disease‐Specific Dopaminergic Neurons for High Content Phenotyping and Drug Testing
Bolognin, S., Fossépré, M., Qing, X., Jarazo, J., Ščančar, J., Moreno, E. L., Nickels, S., Wasner, K., Ouzren-Zarhloul, N., Walter, J., et al. (2018) · Advanced Science · doi:10.1002/advs.201800927 · Cited by 151
What causes cell death in Parkinson's disease?
Gupta, A., Dawson, V. L., & Dawson, T. M. (2009) · Annals of Neurology · doi:10.1002/ana.21573 · Cited by 148
Striatal Neuroinflammation Promotes Parkinsonism in Rats
Choi, D.-Y., Liu, M., Hunter, R. L., Cass, W. A., Pandya, J. D., Sullivan, P. G., Shin, E.-J., Kim, H.-C., Gash, D. M., & Bing, G. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005482 · Cited by 141
Protective Mechanisms of Flavonoids in Parkinson’s Disease
Magalingam, K. B., Radhakrishnan, A. K., & Haleagrahara, N. (2015) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2015/314560 · Cited by 144
Back to the tubule: microtubule dynamics in Parkinson’s disease
Pellegrini, L., Wetzel, A., Grannò, S., Heaton, G., & Harvey, K. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2351-6 · Cited by 147
The PINK1/Parkin pathway: a mitochondrial quality control system?
Whitworth, A. J., & Pallanck, L. J. (2009) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-009-9253-3 · Cited by 137
“…humans and animal models (Betarbet et al. 2002; Corti et al. 2005); a high proportion of sporadic PD patients exhibit systemic mitochondrial defects (Schapira 2007); mitochondrial DNA deletions are present at high abundance in dopamine neurons from aged individuals, and are even more prevalent in…”
Background
Alpha-Synuclein as a Biomarker of Parkinson’s Disease: Good, but Not Good Enough
Ganguly, U., Singh, S., Pal, S., Prasad, S., Agrawal, B. K., Saini, R. V., & Chakrabarti, S. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.702639 · Cited by 139
“Mitochondrial complex I inhibition in substantia nigra in postmortem PD brain was an early finding which was later reported in platelets and skeletal muscles of PD patients (Schapira, 2007).”
Background
Natural Phytochemicals as Novel Therapeutic Strategies to Prevent and Treat Parkinson’s Disease: Current Knowledge and Future Perspectives
Balakrishnan, R., Azam, S., Cho, D.-Y., Su-Kim, I., & Choi, D. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/6680935 · Cited by 117
“In addition, preclinical and clinical findings have revealed that brain and cerebrospinal fluid samples from PD patients contain significantly higher levels of oxidized coenzyme Q10 and the nuclear DNA oxidation biomarker 8-OHdG, establishing the existence of oxidative damage to DNA and mitochondria in PD patients [59…”
Background
Dietary Factors in the Etiology of Parkinson’s Disease
Ağım, Z. S., & Cannon, J. R. (2015) · BioMed Research International · doi:10.1155/2015/672838 · Cited by 115
Mitochondrial DNA, base excision repair and neurodegeneration
de Souza-Pinto, N. C., Wilson, D. M., Stevnsner, T., & Bohr, V. A. (2008) · DNA repair · doi:10.1016/j.dnarep.2008.03.011 · Cited by 102
Dietary fat intake and risk of Parkinson's disease: A case-control study in Japan
Miyake, Y., Sasaki, S., Tanaka, K., Fukushima, W., Kiyohara, C., Tsuboi, Y., Yamada, T., Oeda, T., Miki, T., Kawamura, N., et al. (2009) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2009.09.021 · Cited by 100
Does Ceruloplasmin Defend Against Neurodegenerative Diseases?
Wang, B., & Wang, X. (2018) · Current Neuropharmacology · doi:10.2174/1570159x16666180508113025 · Cited by 104
Coenzyme Q10 Depletion in Medical and Neuropsychiatric Disorders: Potential Repercussions and Therapeutic Implications
Morris, G., Anderson, G., Berk, M., & Maes, M. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8477-8 · Cited by 96
The Impact of Pathogenic Mitochondrial DNA Mutations on Substantia Nigra Neurons
Reeve, A. K., Meagher, M., Lax, N., Simcox, E. M., Hepplewhite, P. D., Jaros, E., & Turnbull, D. M. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.3525-12.2013 · Cited by 94
Chemopreventative effects of tetrahydrocurcumin on human diseases
Wu, J.-C., Tsai, M.-L., Lai, C., Wang, Y., Ho, C., & Pan, M. (2013) · Food & Function · doi:10.1039/c3fo60370a · Cited by 92
Maternal transmission of Alzheimer's disease: prodromal metabolic phenotype and the search for genes
Mosconi, L., Berti, V., Swerdlow, R. H., Pupi, A., Duara, R., & de Leon, M. (2010) · Human Genomics · doi:10.1186/1479-7364-4-3-170 · Cited by 85
Nuclear factor‐kappa B (NF‐κB) in pathophysiology of Parkinson disease: Diverse patterns and mechanisms contributing to neurodegeneration
Dolatshahi, M., Hameghavandi, M. H. R., Sabahi, M., & Rostamkhani, S. (2021) · European Journal of Neuroscience · doi:10.1111/ejn.15242 · Cited by 87
“This phenomenon leads to oxidative stress and thereby selective neurodegeneration (Li, Niu, et al., 2019; Schapira, 2007).”
Background
Mitochondrial Dysfunction in Neurodegenerative Diseases
Schapira, A. H. V. (2008) · Neurochemical Research · doi:10.1007/s11064-008-9855-x · Cited by 85
Self-citation
LRRK2 deficiency induced mitochondrial Ca2+ efflux inhibition can be rescued by Na+/Ca2+/Li+ exchanger upregulation
Ludtmann, M. H. R., Kostić, M., Horne, A., Gandhi, S., Sekler, I., & Abramov, A. Y. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1469-5 · Cited by 83
Progress in neuroprotection in Parkinson’s disease
Schapira, A. H. V. (2008) · European Journal of Neurology · doi:10.1111/j.1468-1331.2008.02055.x · Cited by 82
Self-citation
Alterations in mitochondrial dynamics induced by tebufenpyrad and pyridaben in a dopaminergic neuronal cell culture model
Charli, A., Jin, H., Anantharam, V., Kanthasamy, A., & Kanthasamy, A. G. (2015) · NeuroToxicology · doi:10.1016/j.neuro.2015.06.007 · Cited by 81
Mitochondrial Pathology in Parkinson's Disease
Schapira, A. H. V. (2011) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20303 · Cited by 83
Self-citation
Selective neuronal vulnerability in Parkinson's disease
González‐Rodríguez, P., Zampese, E., & Surmeier, D. J. (2020) · Progress in brain research · doi:10.1016/bs.pbr.2020.02.005 · Cited by 80
MUTYH DNA glycosylase: the rationale for removing undamaged bases from the DNA
Markkanen, E., Dorn, J., & Hübscher, U. (2013) · Frontiers in Genetics · doi:10.3389/fgene.2013.00018 · Cited by 84
Alpha‐synuclein aggregation and cell death triggered by energy deprivation and dopamine overload are counteracted by D2/D3 receptor activation
Bellucci, A., Collo, G., Sarnico, I., Battistin, L., Missale, C., & Spano, P. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05406.x · Cited by 77
“…activity has been observed in the substantia nigra (SN) of patients affected by PD (Ambani et al. 1975; Kish et al. 1985; Marttila et al. 1988; Saggu et al. 1989; Sian et al. 1994; Fukae et al. 2007) and mitochondrial dysfunctions are known to be involved in PD pathogenesis (Schapira 2007).”
Background
KNS‐760704 [(6R)‐4,5,6,7‐tetrahydro‐N6‐propyl‐2, 6‐benzothiazole‐diamine dihydrochloride monohydrate] for the Treatment of Amyotrophic Lateral Sclerosis
Gribkoff, V. K., & Bozik, M. E. (2008) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2008.00048.x · Cited by 77
Elucidating Differences in the Hepatotoxic Potential of Tolcapone and Entacapone With DILIsym ® , a Mechanistic Model of Drug‐Induced Liver Injury
Longo, D., Yang, Y., Watkins, P. B., Howell, B. A., & Siler, S. (2016) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12053 · Cited by 73
Mitochondrial function and autophagy: integrating proteotoxic, redox, and metabolic stress in Parkinson's disease
Zhang, J., Culp, M. L., Craver, J., & Darley-Usmar, V. M. (2018) · Journal of Neurochemistry · doi:10.1111/jnc.14308 · Cited by 74
“…dysfunction have been found in postmortem Parkinson’s disease brains (Bindoff et al. 1989; Schapira et al. 1990; Parker and Swerdlow 1998; Beal 2003; Schapira 2007; Chu et al. 2009; Swerdlow 2009; Ryan et al. 2015), as well as dopaminergic neurons derived from patients with idiopathic and familial…”
Background
Changes in endoplasmic reticulum stress proteins and aldolase A in cells exposed to dopamine
Dukes, A. A., Laar, V. S. V., Cascio, M., & Hastings, T. G. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05392.x · Cited by 71
“…DAQ has been shown to inhibit the activity of mitochondrial protein complexes (including complex I), to uncouple mitochondrial respiration, and to open the permeability transition pore (Ben-Shachar et al. 1995; Berman and Hastings 1999; Li and Dryhurst 2001; Khan et al. 2005; Schapira 2007).”
Background
Alpha-synuclein mitochondrial interaction leads to irreversible translocation and complex I impairment
Martínez, J. H., Fuentes, F., Vanasco, V., Álvarez, S., Alaimo, A., Cassina, A., Leskow, F. C., & Velazquez, F. (2018) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2018.04.018 · Cited by 78
Nanomicellar formulation of coenzyme Q10 (Ubisol-Q10) effectively blocks ongoing neurodegeneration in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model: potential use as an adjuvant treatment in Parkinson's disease
Sikorska, M., Lanthier, P., Miller, H., Beyers, M., Sodja, C., Zurakowski, B., Gangaraju, S., Pandey, S., & Sandhu, J. K. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.03.032 · Cited by 70
SLP-2 interacts with Parkin in mitochondria and prevents mitochondrial dysfunction in Parkin-deficient human iPSC-derived neurons andDrosophila
Zanon, A., Kalvakuri, S., Raković, A., Foco, L., Guida, M., Schwienbacher, C., Serafin, A., Rudolph, F., Trilck, M., Grünewald, A., et al. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx132 · Cited by 70
Crocin protects PC12 cells against MPP+-induced injury through inhibition of mitochondrial dysfunction and ER stress
Zhang, G.-F., Zhang, Y., & Zhao, G. (2015) · Neurochemistry International · doi:10.1016/j.neuint.2015.07.011 · Cited by 67
Serological Profiles of Urate, Paraoxonase-1, Ferritin and Lipid in Parkinson’s Disease: Changes Linked to Disease Progression
Ikeda, K., Nakamura, Y., Kiyozuka, T., Aoyagi, J., Hirayama, T., Nagata, R., Ito, H., Iwamoto, K., Murata, K., Yoshii, Y., et al. (2011) · Neurodegenerative Diseases · doi:10.1159/000323265 · Cited by 66
Insights on altered mitochondrial function and dynamics in the pathogenesis of neurodegeneration
McInnes, J. (2013) · Translational Neurodegeneration · doi:10.1186/2047-9158-2-12 · Cited by 65
Mitochondrial therapies for Parkinson's disease
Thomas, B., & Beal, M. F. (2010) · Movement Disorders · doi:10.1002/mds.22781 · Cited by 62
Granulocyte–macrophage colony‐stimulating factor promotes survival of dopaminergic neurons in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐induced murine Parkinson’s disease model
Kim, N. K., Choi, B. H., Huang, X., Snyder, B., Bukhari, S., Kong, T., Park, H., Park, H. C., Park, S. R., & Ha, Y. S. (2009) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2009.06653.x · Cited by 63
“…not clearly understood, a variety of molecular mechanisms have been proposed to explain the dopaminergic cell death phenomenon, including mitochondrial dysfunction, oxidative stress, and activation of microglia in the substantia nigra (Abou-Sleiman et al., 2006; Block et al., 2007; Schapira, 2007).”
Background
Peroxisome proliferator-activated receptor-γ (PPARγ) agonist is neuroprotective and stimulates PGC-1α expression and CREB phosphorylation in human dopaminergic neurons
Mäkelä, J., Tselykh, T. V., Kukkonen, J. P., Eriksson, O., Korhonen, L., & Lindholm, D. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.11.020 · Cited by 59
In vitro analysis of cell metabolism using a long-decay pH-sensitive lanthanide probe and extracellular acidification assay
Hynes, J., O’Riordan, T. C., Zhdanov, A. V., Uray, G., Will, Y., & Papkovsky, D. B. (2009) · Analytical Biochemistry · doi:10.1016/j.ab.2009.04.016 · Cited by 58
Ubiquitin phosphorylation in Parkinson’s disease: Implications for pathogenesis and treatment
Chin, L., & Li, L. (2016) · Translational Neurodegeneration · doi:10.1186/s40035-015-0049-6 · Cited by 59
Multifunctional role of natural products for the treatment of Parkinson’s disease: At a glance
Rahman, M. M., Wang, X., Islam, M. R., Akash, S., Supti, F. A., Mitu, M. I., Harun-Or-Rashid, M., Aktar, M. N., Kali, M. S. K., Jahan, F. I., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.976385 · Cited by 60
Genetics and iron in the systems biology of Parkinson’s disease and some related disorders
Funke, C., Schneider, S. A., Berg, D., & Kell, D. B. (2012) · Neurochemistry International · doi:10.1016/j.neuint.2012.11.015 · Cited by 54
“…2005; Danielson et al., 2011; Dawson and Dawson, 2003; Fato et al., 2008b; Henchcliffe and Beal, 2008; Perier et al., 2007; Schapira et al., 1989; Schapira, 2007; Sterky et al., 2012; Winklhofer and Haass, 2010), increased excitotoxicity, altered calcium homeostasis (Lang, 2007; Maetzler et al.,…”
The lifelong maintenance of mesencephalic dopaminergic neurons by Nurr1 and engrailed
Alavian, K. N., Jeddi, S., Naghipour, S. I., Nabili, P., Licznerski, P., & Tierney, T. S. (2014) · Journal of Biomedical Science · doi:10.1186/1423-0127-21-27 · Cited by 53
MALDI-TOF MS Profiling of Annonaceous Acetogenins in Annona muricata Products for Human Consumption
Champy, P., Guérineau, V., & Laprévôte, O. (2009) · Molecules · doi:10.3390/molecules14125235 · Cited by 53
The antioxidant Trolox helps recovery from the familial Parkinson's disease-specific mitochondrial deficits caused by PINK1- and DJ-1-deficiency in dopaminergic neuronal cells
Shim, J. H., Yoon, S. H., Kim, K., Han, J., Ha, J., Hyun, D. H., Paek, S. H., Kang, U. J., Zhuang, X., & Son, J. H. (2011) · Mitochondrion · doi:10.1016/j.mito.2011.05.013 · Cited by 55
Relationship between high dietary fat intake and Parkinson’s disease risk: a meta-analysis
Sun, Q., Qu, Y., Chen, X., & Xu, M. (2019) · Neural Regeneration Research · doi:10.4103/1673-5374.262599 · Cited by 51
Extremely Low Frequency Magnetic Field (ELF-MF) Exposure Sensitizes SH-SY5Y Cells to the Pro-Parkinson’s Disease Toxin MPP+
Benassi, B., Filomeni, G., Montagna, C., Merla, C., Lopresto, V., Pinto, R., Marino, C., & Consales, C. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9354-4 · Cited by 50
DJ-1 cooperates with PYCR1 in cell protection against oxidative stress
Yasuda, T., Kaji, Y., Agatsuma, T., Niki, T., Arisawa, M., Shuto, S., Ariga, H., & Iguchi‐Ariga, S. M. M. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.05.095 · Cited by 51
The Effects of Dietary Interventions on Brain Aging and Neurological Diseases
Lobo, F., Haase, J., & Brandhorst, S. (2022) · Nutrients · doi:10.3390/nu14235086 · Cited by 54
“α-synuclein aggregation and mitochondrial dysfunction exacerbate each other and are both important elements in PD pathogenesis [89,90,92].”
Background
Hax1 lacks BH modules and is peripherally associated to heavy membranes: implications for Omi/HtrA2 and PARL activity in the regulation of mitochondrial stress and apoptosis
Jeyaraju, D. V., Cisbani, G., de Brito, O. M., Koonin, E. V., & Pellegrini, L. (2009) · Cell Death and Differentiation · doi:10.1038/cdd.2009.110 · Cited by 48
N-Acetylcysteine Nanocarriers Protect against Oxidative Stress in a Cellular Model of Parkinson’s Disease
Mursaleen, L., Noble, B., Chan, S. H. Y., Somavarapu, S., & Zariwala, M. G. (2020) · Antioxidants · doi:10.3390/antiox9070600 · Cited by 51
The role of mitochondrial disturbances in Alzheimer, Parkinson and Huntington diseases
Carvalho, C., Correia, S. C., Cardoso, S., Plácido, A. I., Candeias, E., Duarte, A. I., & Moreira, P. I. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.1058160 · Cited by 45
Metformin as a Potential Neuroprotective Agent in Prodromal Parkinson's Disease—Viewpoint
Sportelli, C., Urso, D., Jenner, P. G., & Chaudhuri, К. R. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00556 · Cited by 47
Dietary fat intake and risk for Parkinson's disease
Dong, J., Beard, J. D., Umbach, D. M., Park, Y., Huang, X., Blair, A. E., Kamel, F., & Chen, H. (2014) · Movement Disorders · doi:10.1002/mds.26032 · Cited by 42
Expression of Lewy body protein septin 4 in postmortem brain of Parkinson's disease and control subjects
Shehadeh, L. A., Mitsi, G., Adi, N., Bishopric, N. H., & Papapetropoulos, S. (2008) · Movement Disorders · doi:10.1002/mds.22306 · Cited by 42
Reinforcing mitochondrial functions in aging brain: An insight into Parkinson's disease therapeutics
Chandra, G., Shenoi, R. A., Anand, R., Rajamma, U., & Mohanakumar, K. P. (2017) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2017.12.004 · Cited by 39
Long Non-coding RNAs in Parkinson’s Disease
Xin, C., & Liu, J. (2021) · Neurochemical Research · doi:10.1007/s11064-021-03230-3 · Cited by 39
Differential submitochondrial localization of PINK1 as a molecular switch for mediating distinct mitochondrial signaling pathways
Fallaize, D., Chin, L., & Li, L. (2015) · Cellular Signalling · doi:10.1016/j.cellsig.2015.09.020 · Cited by 38
The Importance of Mitophagy in Maintaining Mitochondrial Function in U373MG Cells. Bafilomycin A1 Restores Aminochrome-Induced Mitochondrial Damage
Huenchuguala, S., Muñoz, P., & Segura‐Aguilar, J. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00152 · Cited by 38
Variants in SNCA Gene Are Associated with Parkinson’s Disease Risk and Cognitive Symptoms in a Brazilian Sample
Campêlo, C. L. D. C., Cagni, F. C., Figueredo, D. D. S., de Oliveira, L. G., Silva-Neto, A. B., Macêdo, P. T., dos Santos, J. R., Izídio, G. S., Ribeiro, A. M., de Andrade, T. G., et al. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00198 · Cited by 36
Chronic Dichlorvos Exposure: Microglial Activation, Proinflammatory Cytokines and Damage to Nigrostriatal Dopaminergic System
Binukumar, B. K., Bal, A., & Gill, K. D. (2011) · NeuroMolecular Medicine · doi:10.1007/s12017-011-8156-8 · Cited by 36
Novel insights into the role of circular RNAs in Parkinson disease: An emerging renaissance in the management of neurodegenerative diseases
Dorostgou, Z., Yadegar, N., Dorostgou, Z., Khorvash, F., & Vakili, O. (2022) · Journal of Neuroscience Research · doi:10.1002/jnr.25094 · Cited by 35
αSynuclein and Mitochondrial Dysfunction: A Pathogenic Partnership in Parkinson’s Disease?
Protter, D. S. W., Lang, C., & Cooper, A. A. (2012) · Parkinson s Disease · doi:10.1155/2012/829207 · Cited by 38
Intrinsic Effects of Gold Nanoparticles on Oxygen–Glucose Deprivation/Reperfusion Injury in Rat Cortical Neurons
Zheng, Y., Wu, Y., Liu, Y., Guo, Z., Bai, T., Zhou, P., Wu, J. S., Yang, Q., Liu, Z., & Lu, X. (2019) · Neurochemical Research · doi:10.1007/s11064-019-02776-7 · Cited by 32
Crosstalk of organelles in Parkinson’s disease – MiT family transcription factors as central players in signaling pathways connecting mitochondria and lysosomes
Lang, M., Pramstaller, P. P., & Pichler, I. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00555-7 · Cited by 35
Mitochondrial dysfunction in Parkinson’s disease
Бунеева, О. А., & Medvedev, A. E. (2011) · Biochemistry (Moscow) Supplement Series B Biomedical Chemistry · doi:10.1134/s1990750811040032 · Cited by 30
Natural Molecules From Chinese Herbs Protecting Against Parkinson’s Disease via Anti-oxidative Stress
Ding, Y., Xin, C., Zhang, C., Lim, K., Zhang, H., Fu, Z., Li, L., & Huang, W. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00246 · Cited by 28
“Mutation of genes involved in mitochondrial homeostasis was known to induce familial PD (Schapira, 2007).”
Background
From Brain to Muscle: The Role of Muscle Tissue in Neurodegenerative Disorders
Duranti, E., & Villa, C. (2024) · Biology · doi:10.3390/biology13090719 · Cited by 31
“Similarly, in PD, α -syn aggregates form Lewy bodies in the brain and have been detected in muscle tissue, compromising cellular homeostasis [214].”
Background
Oral pre-treatment with epigallocatechin gallate in 6-OHDA lesioned rats produces subtle symptomatic relief but not neuroprotection
Leaver, K. R., Allbutt, H. N., Creber, N. J., Kassiou, M., & Henderson, J. M. (2009) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2009.08.013 · Cited by 27
A Cybrid Cell Model for the Assessment of the Link Between Mitochondrial Deficits and Sporadic Parkinson’s Disease
Arduíno, D. M., Esteves, A. R., Swerdlow, R. H., & Cardoso, S. M. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-2288-8_31 · Cited by 27
Exposure to Phosphoglycerate Kinase 1 Activators and Incidence of Parkinson's Disease
Gros, P., Wang, X., Guan, J., Lang, A. E., Austin, P. C., Welk, B. K., Visanji, N. P., & Marras, C. (2021) · Movement Disorders · doi:10.1002/mds.28712 · Cited by 26
Involvement of antioxidant enzymes in Parkinson’s disease
Tahavvori, A., Gargari, M. K., Yazdani, Y., Mamalo, A. S., Beilankouhi, E. A. V., & Valilo, M. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154757 · Cited by 28
Impaired mitochondrial functions and energy metabolism in MPTP-induced Parkinson’s disease: comparison of mice strains and dose regimens
Pathania, A., Garg, P., & Sandhir, R. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00840-2 · Cited by 25
“Furthermore, reduced citrate synthase activity has been supported by Schapira (2007) in the SNregion of patients with multiple system atrophy (Parkinsonianlike disorder).”
Background
Protective Effects of the Caffeine Against Neurodegenerative Diseases
Tellone, E., Galtieri, A., Russo, A., & Ficarra, S. (2017) · Current Medicinal Chemistry · doi:10.2174/0929867324666171009104040 · Cited by 25
Disrupted Mitochondrial and Metabolic Plasticity Underlie Comorbidity between Age-Related and Degenerative Disorders as Parkinson Disease and Type 2 Diabetes Mellitus
Juárez‐Flores, D. L., Ezquerra, M., González‐Casacuberta, I., Ormazábal, A., Morén, C., TOLOSA, E. S., Fucho, R., Guitart‐Mampel, M., Casado, M., Valldeoriola, F., et al. (2020) · Antioxidants · doi:10.3390/antiox9111063 · Cited by 24
“Specifically, mitochondrial respiratory chain (MRC) dysfunction, oxidative stress, altered mitochondrial dynamics, and morphology have been reported in iPD [21].”
Background
Convergent Molecular Pathways in Type 2 Diabetes Mellitus and Parkinson’s Disease: Insights into Mechanisms and Pathological Consequences
Sandeep, X. X. X. X., Ahmad, M. H., Rani, L., & Mondal, A. C. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-02867-7 · Cited by 24
Curcumin and N-Acetylcysteine Nanocarriers Alone or Combined with Deferoxamine Target the Mitochondria and Protect against Neurotoxicity and Oxidative Stress in a Co-Culture Model of Parkinson’s Disease
Mursaleen, L., Chan, S. H. Y., Noble, B., Somavarapu, S., & Zariwala, M. G. (2023) · Antioxidants · doi:10.3390/antiox12010130 · Cited by 23
Exercise and mitochondrial remodeling to prevent age-related neurodegeneration
O’Reilly, C. L., Miller, B. F., & Lewis, T. L. (2022) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00611.2022 · Cited by 25
Docosahexaenoic acid protection in a rotenone induced Parkinson's model: Prevention of tubulin and synaptophysin loss, but no association with mitochondrial function
Serrano‐García, N., Fernández‐Valverde, F., Luis‐García, E. R., Granados-Rojas, L., Juárez-Zepeda, T. E., Orozco-Suárez, S. A., Pedraza‐Chaverrí, J., Orozco‐Ibarra, M., & Jiménez‐Anguiano, A. (2018) · Neurochemistry International · doi:10.1016/j.neuint.2018.10.015 · Cited by 23
“Indeed, mitochondrial complex I activity decreases between 20 and 30% in the SNpc and frontal cortex in patients with idiopathic PD (Schapira, 2007; Navarro et al., 2009; Chaturvedi and Beal, 2013).”
Cross-talk between α-synuclein and the microtubule cytoskeleton in neurodegeneration
Mazzetti, S., Calogero, A. M., Pezzoli, G., & Cappelletti, G. (2022) · Experimental Neurology · doi:10.1016/j.expneurol.2022.114251 · Cited by 22

Authors: Schapira, A. H. V.
Affiliations: The Royal Free Hospital (GB)
Corresponding author: Schapira, A H V
ORCID: Schapira, A H V
Venue: Cell Death & Differentiation
Publisher: Springer Science and Business Media LLC
Published: 2007-04-27
Volume: 14
Issue: 7
Pages: 1261-1266
ISSN: 1350-9047 (ISSN-L)
1476-5403
DOI: 10.1038/sj.cdd.4402160
OpenAlex: W1990162995
Cited by: 175
References: 95
Citations by year: 2026: 5 · 2025: 7 · 2024: 7 · 2023: 7 · 2022: 13 · 2021: 12 · 2020: 10 · 2019: 8 · 2018: 9 · 2017: 9 · 2016: 3 · 2015: 13 · 2014: 7 · 2013: 14 · 2012: 6
FWCI: 1.46
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Cell Death and Differentiation (publishedVersion)
PubMed (publishedVersion)
UCL Discovery (University College London) (submittedVersion)
Topics: Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
Keywords: Parkinson's disease, mitochondrial dysfunction, dopaminergic neuron loss, substantia nigra, PINK1, DJ-1, OMI, PARK genes, familial Parkinson's disease, sporadic Parkinson's disease, oxidative damage, neuroinflammation, proteasomal dysfunction, mitochondrial respiratory chain, genetic mutations
MeSH terms: Protein Deglycase DJ-1, PTEN-Induced Putative Kinase, Animals, DNA, Mitochondrial, Humans, Mitochondria, Mutation, Parkinson Disease, Protein Kinases, Oncogene Proteins, Mitochondrial Diseases, Electron Transport Complex I, Ubiquitin-Protein Ligases, Intracellular Signaling Peptides and Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Mitochondrial dysfunction in Parkinson's disease

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks